Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary fibrosis (IPF), but treatment use remains at ∼60%. Objective: To investigate the views of individuals with IPF and pulmonologists on the diagnosis and management of IPF to understand treatment patterns. Methods: Interviews and/or online surveys were completed by patients and pulmonologists from Canada, France, Germany, Italy, Spain, and the UK. Responses from physicians were analyzed by time between diagnosis and treatment initiation in the majority of patients with IPF (group A, > 4 months; group B, ≤4 months). Statistical comparisons between physicians were undertaken using z tests, with p < 0.05 considered statistically significant. Results: The physicians in group A saw fewer patients, were less comfortable discussing the IPF prognosis with patients, and had less belief in the benefits of antifibrotic treatments than the physicians in group B. These physicians' attitudes contrasted with those of the patients, who wanted more information about the IPF prognosis and pharmacological treatment options at diagnosis and were more concerned about preventing disease progression than avoiding medication side effects. Differences between countries were found regarding physicians' comfort in discussing the prognosis at diagnosis and access to care. Conclusions: Several barriers to antifibrotic treatment, principally reflecting the differing views and values of patients and physicians, were identified in this study, suggesting a need for better patient-physician communication about pharmacological therapy for IPF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, invariably fatal, scarring lung disorder of unknown cause [1, 2] that significantly lowers quality of life [3] and has a survival rate lower than that reported for many common cancers [2, [4] [5] [6] [7] . The incidence and prevalence of IPF, as well as the number of deaths from IPF, are currently increasing [8] [9] [10] .
The clinical course of IPF is variable, and there is no good way to accurately predict prognosis or directly assess treatment response in individual patients; all patients with IPF will invariably experience lung functional decline at some point in their disease course [2, [11] [12] [13] . Currently there are two antifibrotic drugs, pirfenidone and nintedanib, approved for the treatment of IPF; these therapies are recommended in universally accepted, international treatment guidelines [14] . Recent evidence from post hoc analyses supports early initiation of antifibrotic therapy once patients have been diagnosed with IPF to reduce loss of lung function and slow disease progression [15] [16] [17] [18] . However, despite the availability of effective treatments, ∼40% of patients with a confirmed diagnosis of IPF do not receive treatment [19] .
Here, we present the results of qualitative and quantitative surveys among pulmonologists and individuals with IPF that aimed to explore views on the diagnosis, treatment, and management of IPF. We also sought to identify differences in behavior between pulmonologists who commenced antifibrotic treatment ≤4 months after diagnosis and those who preferred to "watch and wait."
Methods

Design and Participants
Data for this study, comprising qualitative interviews and quantitative online questionnaires, were collected from individuals with IPF ("patients") and pulmonologists ("physicians") from Canada, France, Germany, Italy, Spain, and the UK. The interviews and questionnaires were developed by Hall & Partners, an independent market research agency, on behalf of F. HoffmannLa Roche, Ltd. The participants were made aware that this study was sponsored by a pharmaceutical company.
Between July 27 and September 16, 2016, 60-min face-to-face interviews were conducted with the patients and physicians by professional market research moderators and were supplemented by telephone interviews with the physicians. Caregivers could participate in the interviews to support the patients. Subsequently, the patients and physicians participated in 20-min online surveys between September 23 and October 12, 2016. Different surveys were used by the patients and physicians (online suppl. Files 1 and 2; see www.karger.com/doi/10.1159/000490667 for all online suppl. material), and both surveys were provided in English, French, German, Italian, and Spanish. Because the surveys contained no identifying information, there may have been an overlap between those participating in face-to-face interviews and those taking part in online surveys.
Responses were collected from patients with IPF, and from physicians who had > 5 patients with IPF consulting them within the previous 3 months and were responsible for the initiation (or recommending the initiation) of any approved drug treatment for IPF (for the face-to-face interviews, physicians were required to be personally responsible for initiating treatment).
Patients were recruited via physician referrals, patient groups, or market research panels and were eligible for inclusion if they had received pirfenidone and/or nintedanib, or had been offered (but refused) treatment. Since prescription of antifibrotics is restricted to certain centers in the UK and Italy, ≥50% of the physicians in the UK and ≥67% of the physicians in Italy were required to work at centers authorized to prescribe antifibrotics for the online questionnaire; these thresholds were selected based on previous research on the treatment of IPF. This threshold was subsequently removed from the UK to allow a large enough sample of physicians to be included in the study within the time that the survey was available. Physicians were recruited from market research panels and were required to complete the surveys themselves. The patients and physicians received a small cash incentive for participation in the research (e.g., in the UK, patients received GBP 20 and physicians received GBP 44; this value varied by country).
Statistical Analysis
The face-to-face interviews were recorded and transcribed, translated into English (if applicable), and collated. The responses collected in the online questionnaires were collated, and statistical analyses were performed by the research team at Hall & Partners using Askiaanalysis (Askia, Paris, France).
The physicians were split into two groups according to the responses that were collected in the online questionnaires: those who monitored ≥50% of patients for > 4 months after the diagnosis before initiating antifibrotic treatment (group A) and those who initiated antifibrotic treatment within 4 months after the diagnosis in the majority of patients (group B). The 4-month threshold was based on observations from the qualitative interviews indicating that physicians who tended to initiate treatment early would either do so at diagnosis or at a follow-up appointment within 3 months of diagnosis, whereas those who waited before initiating treatment would usually schedule a follow-up appointment ≥6 months after the diagnosis.
The physicians' responses were also analyzed based on tertiles of their caseloads (high, medium, or low) of patients with "mild" or "moderate" IPF (no definition of "mild" or "moderate" IPF was provided, and the assessment of disease severity was based solely on the judgment of the individual physicians). Statistical comparisons between physicians were undertaken using z tests, with p < 0.05 considered statistically significant.
Results
Physician Characteristics
Sixty-one physicians participated in the face-to-face interviews and 287 completed the online questionnaires (online suppl. Table S1 ). The proportion of physicians who were authorized to prescribe antifibrotics was 80% in the UK and 75% in Italy (this question was not asked in the other countries, since they did not have the same restrictions on which centers could prescribe antifibrotics). Of the physicians who completed the online questionnaires, 46% were in group A and 54% were in DOI: 10.1159/000490667 group B (online suppl. Table S1 ). The gender and age distri butions of physicians in groups A and B were similar (Table 1) .
Overall, 11% of the physicians worked in specialist pulmonary centers or tertiary referral centers for IPF; this did not differ significantly between groups A and B ( 
Patient Characteristics
Sixty-eight patients participated in the face-to-face interviews and 60 patients completed the online questionnaires (online suppl. Table S1 ). The mean age of the patients who completed the online surveys was 64.6 (±9.0) years, and 72% (43/60) were male. All patients had been treated with pirfenidone (73% [44/60]), nintedanib (18% [11/60] ), or both treatments sequentially (pirfenidone then nintedanib; 8% [5/60] ). At the time they completed the survey, 77% (46/60) of the patients were still receiving (22) Values are presented as n (%). * Had a significantly higher proportion of physicians with this response than in the other group (p < 0.05). IPF, idiopathic pulmonary fibrosis.
a Physicians who monitored ≥50% of patients for >4 months after the diagnosis before initiating antifibrotic treatment.
b Physicians who initiated antifibrotic treatment within 4 months after the diagnosis in the majority of patients.
c One physician in group B did not provide their age.
d Specialist center was defined by physicians. e Any practice based outside the hospital or in a community setting.
f IPF was defined as "mild" by the physicians; mean caseload in previous year: high = 133.7 patients, medium = 28.7 patients, and low = 9.4 patients. g IPF was defined as "moderate" by the physicians; mean caseload in previous year: high = 141.4 patients, medium = 18.9 patients, and low = 8.8 patients.
Respiration 2018;96:514-524 DOI: 10.1159/000490667 treatment and 22% (13/60) had stopped treatment (1 patient gave their treatment status as "other").
Physician Survey: Diagnosis
The topics the physicians reported discussing at diagnosis are shown in Table 2 . Significantly more physicians with high caseloads (60% [55/91]) than physicians with low caseloads (44% [38/86] ; p < 0.05) discussed the prognosis at diagnosis. The topics discussed at diagnosis by country are shown in online suppl. Table S2 .
Only 28% of the physicians "strongly agreed" or "agreed" that they were comfortable discussing the IPF prognosis (Table 2) , with a significant difference between groups A and B (p < 0.05; Table 2 ). Similarly, there were differences at the country level (online suppl. Table S2) .
A considerable proportion of the physicians (40%) avoided discussing the typical prognosis or life expectancy with IPF even when a patient asked about this, with more physicians in group A than in group B avoiding these questions by their patients ( Table 2) . Some of the physicians who participated in face-to-face interviews also expressed concerns about how to discuss prognosis with their patients: "My approach is not to confirm diagnosis but to think how do I let this patient know that this [IPF] is a serious illness without scaring them?" [Physician -Canada] "If you tell a patient or their family that you would rather wait [to start treatment] right after you've told them that they have a fatal disease, they think you're completely nuts [crazy] . Sometimes, I feel there is only little that can be done with the treatments but it is difficult not to offer something." [Physician -France] Patient Survey: Diagnosis Twenty-seven patients (45%) were informed of their diagnosis by a pulmonologist based at a large teaching or specialist hospital; others were informed of their diagnosis by a pulmonologist based at a local city/district hospital (28%) or office (15%), by their general practitioner (10%), or by someone else (2%). The majority of the patients had not heard of IPF when they were diagnosed (77% [46/60]). Forty percent (24/60) of the patients did (24) 32 (24) 36 (23) Values are presented as n (%). * Had a significantly higher proportion of physicians with this response than in the other group (p < 0.05). IPF, idiopathic pulmonary fibrosis.
c Physicians who selected "6" or "7" on a 7-point Likert scale, ranging from 1 = "strongly disagree" to 7 = "strongly agree."
DOI: 10.1159/000490667 not feel that they received enough information from their physicians at diagnosis; 57% (34/60) remembered being told that IPF is progressive, 43% (26/60) remembered a discussion on the impact IPF would have on their lives (prognosis), and 43% (26/60) remembered being informed about treatment options. Seventy percent (39/56) of the patients received further information about IPF from their physicians during later appointments, which took place a mean (standard deviation) of 3.8 (7.6) months after the diagnosis (2.0 [1.6] months for the patients treated within 4 months of the diagnosis and 4.5 [8.8] months for the patients treated > 4 months after the diagnosis). Some patients/caregivers participating in the face-toface interviews expressed frustration about the lack of information provided:
"They [physicians] should be a lot more honest… There is no point sugar-coating it. Even if I was fearful of the truth, I would like to hear it… I get the impression that they [physicians] never really know quite how to answer your question… They beat around the bush… They don't give any clear, honest, frank answers you can really understand." [Caregiver -France] "I remember searching on the Internet, and thinking, 'I'll probably be dead next week.' In the beginning, because you know so very little, it can be very frightening. It was so confusing." Physician Survey: Treatment Significantly fewer physicians in group A than in group B agreed or strongly agreed with statements supporting early initiation of antifibrotic therapy (Fig. 1) . Differences in responses to these questions were also observed at the country level (online suppl. Table S3 ). Overall, 23% of the physicians felt that side effects of pharmacological treatment were of more concern than the risk of IPF progression; significantly more physicians in group A than in group B agreed or strongly agreed with this statement (p < 0.05; Fig. 1 ).
Around 50% of the physicians cited "stable" disease, "good" lung function, and/or "asymptomatic" disease as reasons for not treating patients; significantly more phy- sicians in group A than in group B gave these reasons (Fig. 2) , and the majority of the physicians in Canada also gave these reasons for not treating patients (online suppl. Table S4 ).
Other reasons for not treating patients included patients having suspected IPF or an unclear diagnosis, older age (as defined by the physician), comorbidities, the cost of treatment or lack of funding, and access restrictions (i.e., limitations on which patients could receive treatment; Fig. 2) ; none of these differed significantly between groups A and B. Access restrictions were most frequently cited by physicians as a reason for not treating patients in the UK and Canada (online suppl. Table S4 ).
Patient Survey: Treatment
Twenty-five patients (42%) reported that they were offered pharmacological treatment at the same time as receiving their diagnosis. However, only 10% (6/60) of the patients initiated treatment when it was first offered. A further 25% (15/60) of the patients initiated treatment within 4 months of it being offered. Most patients (72% [43/60]) reported that their physician made the final decision on which treatment they received.
Some patients participating in the face-to-face interviews wished that they had started antifibrotic treatment earlier:
"They also said there were treatments that were not available in Spain yet. I even asked her [the doctor] if we could get it, and she told us it was impossible… Those 2 years we were missing [ When asked what advice they would give to someone who had been recently diagnosed with IPF, most patients advised ensuring that they were well informed about IPF, starting treatment, and/or consulting an interstitial lung disease (ILD) specialist: 
Discussion
The results of this study reveal several differences between the physicians who, in the majority of their patients, initiated antifibrotic therapy > 4 months after the diagnosis (group A) and those who did so ≤4 months after the diagnosis (group B). They also highlight a disconnect between physician and patient views regarding information provided at diagnosis and initiation of antifibrotic treatment.
Physicians in group A were less likely to have high caseloads of patients that they defined as having "mild" or "moderate" IPF, less comfortable discussing disease prognosis with their patients, and more likely to avoid this discussion altogether than were physicians in group B. Furthermore, physicians in group A were less likely to believe in the benefits of early treatment of patients with less-advanced disease than were physicians in group B, and they were more likely to be concerned about associated side effects. This is reflected in the finding that a higher proportion of physicians in group A than in group B cited "stable" disease, "good" lung function, and/or "asymptomatic" disease as reasons not to treat "mild" IPF.
Overall, these results suggest that less experience in diagnosing and managing patients with IPF and lack of confidence in the efficacy of antifibrotic treatments, particularly for patients with less-advanced disease, might contribute to lower IPF treatment rates. Additionally, the concept of "stable disease" is a common belief amongst physicians and a frequent reason for not treating IPF; it is possible that the physicians in group A were less concerned about small declines in forced vital capacity (FVC) and had limited access to high-resolution computed tomography to further assess disease progression, but the results from this survey cannot confirm this. Proponents of initiating antifibrotic therapy for all patients with IPF argue that therapy is warranted because IPF causes progressive, irreversible lung damage and has a median survival of approximately 3 years, and because an individual's disease course cannot be accurately predicted [2, [11] [12] [13] . In support of this view, post hoc analyses of CAPACITY [20] and the extension study RECAP [21] comparing annual rates of lung functional decline in patients randomized to pirfenidone or placebo in CAPAC-ITY found that those who had pirfenidone treatment delayed (i.e., the placebo group) had a loss of lung function that was not recovered when open-label pirfenidone was initiated in RECAP [18] . Furthermore, the efficacy of antifibrotic treatment in reducing loss of lung function, regardless of baseline lung function, is supported by clinical evidence [15] [16] [17] 22] . Moreover, half of the physicians surveyed cited older age as a possible barrier to initiating antifibrotic treatment of patients. However, experts believe that age alone should not hinder access to treatment if there are no contraindications present [23] [24] [25] , as is the case for lung cancer [26] .
The patient surveys also revealed that although physicians are still the main source of trusted information for patients with IPF, many patients do not feel that they are provided with enough information about the disease by their physicians. The resulting lack of access to trustworthy information about IPF can be a source of distress for patients and their caregivers. Of concern, there appeared to be a disconnect between the information physicians reported providing and the information patients remembered receiving. For example, 90% of the physicians said they gave their patients information about treatment options, whereas only 43% of the patients remembered being told about IPF treatments. It is well known that some patients do not retain all of the information after one consultation, particularly when bad news is being conveyed [27] [28] [29] ; thus, these findings emphasize the need for physicians to be able to communicate difficult topics with empathy, and to make sure that patients hear and understand them. Physician education in communication skills should emphasize the importance of adjusting the amount, timing, and format of information provided based on the needs and values of the individual patients and their caregivers, and of repeating important informa- tion at multiple visits. Physicians may develop a partnership with their patients by providing comprehensive, effective, and timely information. This promotes informed, shared decision-making and enables patients with IPF to have the best chance of adhering to pharmacological treatments by minimizing potential side effects, as well as incorporating other interventions that may improve outcomes, such as pulmonary rehabilitation [1, 30, 31] .
The majority of the patients surveyed searched for more information on IPF online; however, a recently published analysis found that online health information on IPF is frequently incomplete, inaccurate, and outdated [32] . Results from other surveys suggest that the majority of patients want to be provided with more information about IPF, including its progression and treatment [33, 34] . The European IPF Patient Charter calls for "comprehensive and high-quality information about IPF, including its treatment" to be made available to patients [35] . This is reiterated by Patient Charters from Ireland, the UK, and Canada [31, 36, 37] .
Our results suggest a substantial disconnect between patients and physicians regarding their general attitudes towards treatment. Patients were generally more concerned about slowing IPF progression than medication side effects, and most were confident that they could manage the side effects. Furthermore, most patients would advise others newly diagnosed with IPF to start treatment and/or see an ILD specialist, and some patients expressed frustration or distress that their treatment was not initiated earlier. These views contrasted with the views of some physicians, a large minority of whom were more concerned about antifibrotic drugs causing problematic side effects in their patients than about reducing IPF progression. The IPF international treatment guidelines were updated in 2015 and were co-authored by 16 physicians, 1 scientist, and 1 patient, with no ILD nurses or relatives of patients [14] . There is a need for greater engagement with patients, their families, and patient organizations or advocacy groups when preparing future guidelines or research study designs to ensure that patients' needs, concerns, wishes, and values are adequately and accurately captured.
The survey results also identified differences between countries regarding the discussion of prognosis and the initiation of antifibrotic treatment. These differences could reflect the time that antifibrotic therapy had been available locally (which differed between the countries surveyed), cultural influences, regulatory policies, or various other reasons. Although physicians in Canada were most likely to discuss the prognosis and were more comfortable doing so than physicians from other countries, Canada also had the highest proportion of physicians in group A, presumably due to restrictions on drug reimbursement. Canada (and Spain) had access rules in place that prevented the treatment of patients with an FVC > 80% predicted. Although these rules were lifted in 2016, many physicians in these countries still cited access restrictions as a barrier to treatment in this survey.
Physicians in the UK were least likely to discuss the prognosis with their patients and least comfortable doing so. The UK also had the lowest proportion of physicians who believed in the benefits of early use of antifibrotic treatment or the efficacy of antifibrotics in slowing IPF progression. These results could be due to cultural differences between the UK and Canada and the difference in the time of the launch of antifibrotics between these countries. Additionally, current National Institute for Health and Care Excellence (NICE) guidelines in the UK specify that antifibrotic treatments should only be used in patients with an FVC of 50-80% [38, 39] , thereby excluding patients with limited lung functional impairment. This was reflected in the high proportion of physicians in the UK citing access restrictions as a barrier.
There are a number of limitations to our study. The responses were all self-reported, and the fidelity of the responses (e.g., whether physicians actually waited > 4 months to treat patients) was not assessed. For example, designations of "mild" and "moderate" IPF were based solely on the judgment of the individual physician, and it is unclear what disease parameters were used to define these terms. In addition, the physicians were not asked to provide detailed clinical characteristics or demographics of their patients, rendering it difficult to draw comparisons. Furthermore, the quantitative survey did not allow exploration of the reasoning or rationale behind the responses provided, and may not have identified all reasons for delayed initiation of antifibrotic treatment. Moreover, the physicians in group A were not matched to the physicians in group B. However, most physician characteristics were not significantly different between the groups. Some physicians included in the analysis (20-25% in the UK and Italy) were not authorized to prescribe antifibrotics, which may have affected their responses; however, this reflects treatment practice in the UK and Italy, where the prescription of antifibrotics is limited to certain centers. Although the restriction of antifibrotic prescription to certain centers is not an issue in countries besides the UK and Italy, we cannot be certain that all physicians in these countries were authorized to prescribe antifibrotics.
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Furthermore, the patients who completed the survey were not necessarily treated by the physicians who completed the survey; therefore, definitive conclusions regarding potential disconnects between patients and physicians cannot be drawn from these results. Given that the data were anonymized from the interviews and surveys, it is impossible to know if patients or physicians participated in both the interview and the survey. It is also unclear whether the length of time since patients had been diagnosed affected their responses, since this information was not collected. No data were collected on the rate of disease progression or survival among patients treated by physicians in group A or B, which prevents any direct conclusions from being drawn regarding the effect of delaying initiation of antifibrotic treatment.
The results of the subgroup analyses based on country should be considered with caution due to the lower power of these data compared with the full data set. Additionally, a relatively small number of patients were recruited to participate in the survey, and recruitment may have been biased towards those who are more engaged with their care (e.g., patients recruited via advocacy groups). All patients who participated in this survey had taken antifibrotic treatment; thus, no data could be gained from patients who chose not to receive treatment or who were never offered treatment. Excluding patients who had not been offered antifibrotic treatment may have introduced bias into the responses, as we cannot rule out the possibility that these patients represent a considerable proportion of patients with IPF.
Where patients were recruited by their physicians, there was a risk of selection bias. There may have been selection bias towards patients who had taken pirfenidone, since the research was undertaken for F. Hoffmann-La Roche, Ltd. Also, recruiting via market research panels and providing a cash incentive for completion of the survey may have biased participation; however, it is an effective way to increase the sample size in order to obtain meaningful data from surveys [40] .
In order to address these limitations in future studies, we would suggest conducting this survey as part of a wider real-world study assessing the effect of timing of antifibrotic initiation on IPF progression and survival. The survey could recruit physicians in groups A and B plus a representative sample of patients treated by the physicians in each group within a certain time frame to allow direct comparison of potential disconnects between physicians and patients. The patient population should include patients who have not yet been offered treatment, patients who had refused treatment, and more patients who had taken nintedanib. A definition of "mild" and "moderate" IPF using lung functional parameters could be provided to physicians to homogenize the responses. Additionally, a sample of patients and physicians completing the questionnaire could be invited to face-to-face or telephone interviews to allow further exploration of the responses given.
Conclusions
The results of this survey indicate that physicians who delay antifibrotic treatment see fewer patients with IPF, find it more difficult to discuss the prognosis with these patients, and have less confidence in antifibrotic treatments and their value in treating patients with limited lung functional impairment. The attitudes of physicians contrast with the views of patients, who are more concerned about preventing disease progression than about avoiding medication side effects and want earlier treatment. Additionally, the survey identifies some key differences between countries in terms of access to care, particularly related to prescription/reimbursement restrictions, which may prevent the use of antifibrotic treatment in patients with limited lung functional impairment.
The results of this survey reinforce the recommendations of the European IPF Patient Charter and its call for comprehensive and high-quality information about IPF and equal access to care [35] . We add to this a need for clearer IPF treatment guidelines and better physician education, not only regarding the benefits of early treatment, but also in how to communicate with patients and support them in making informed decisions about their care.
